Aliases & Classifications for Syncope

MalaCards integrated aliases for Syncope:

Name: Syncope 50 28 3

Summaries for Syncope

NINDS : 50 Syncope is a medical term used to describe a temporary loss of consciousness due to the sudden decline of blood flow to the brain. Syncope is commonly called fainting or “passing out.” If an individual is about to faint, he or she will feel dizzy, lightheaded, or nauseous and their field of vision may “white out” or “black out.”  The skin may be cold and clammy.  The person drops to the floor as he or she loses consciousness.  After fainting, an individual may be unconscious for a minute or two, but will revive and slowly return to normal.  Syncope can occur in otherwise healthy people and affects all age groups, but occurs more often in the elderly.  There are several types of syncope.  Vasovagal syncope usually has an easily identified triggering event such as emotional stress, trauma, pain, the sight of blood, or prolonged standing.  Carotid sinus syncope happens because of constriction of the carotid artery in the neck and can occur after turning the head, while shaving, or when wearing a tight collar.  Situational syncope happens during urination, defecation, coughing, or as a result of gastrointestinal stimulation.  Syncope can also be a symptom of heart disease or abnormalities that create an uneven heart rate or rhythm that temporarily affect blood volume and its distribution in the body.  Syncope isn’t normally a primary sign of a neurological disorder, but it may indicate an increased risk for neurologic disorders such as Parkinson’s disease, postural orthostatic tachycardia syndrome (POTS), diabetic neuropathy, and other types of neuropathy.  Certain classes of drugs are associated with an increased risk of syncope, including diuretics, calcium antagonists, ACE inhibitors, nitrates, antipsychotics, antihistamines, levodopa, narcotics, and alcohol.

MalaCards based summary : Syncope is related to ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy and andersen cardiodysrhythmic periodic paralysis. An important gene associated with Syncope is SLC6A2 (Solute Carrier Family 6 Member 2), and among its related pathways/superpathways are Transmission across Chemical Synapses and Circadian entrainment. The drugs Amiodarone and Ranolazine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and brain, and related phenotypes are cardiovascular system and muscle

Related Diseases for Syncope

Diseases related to Syncope via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 311)
# Related Disease Score Top Affiliating Genes
1 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 32.1 KCNH2 KCNJ2 KCNQ1 SCN5A
2 andersen cardiodysrhythmic periodic paralysis 31.7 KCNJ2 KCNQ1 SCN5A
3 catecholaminergic polymorphic ventricular tachycardia 31.6 CALM1 KCNH2 KCNJ2 KCNQ1 SCN5A
4 jervell and lange-nielsen syndrome 1 31.5 CAV3 KCNH2 KCNQ1 SCN5A
5 long qt syndrome 13 31.3 KCNH2 KCNQ1 SCN5A
6 long qt syndrome 12 31.3 KCNH2 KCNQ1 SCN5A
7 long qt syndrome 3 31.3 KCNH2 KCNQ1 SCN5A
8 long qt syndrome 6 30.9 KCNH2 KCNJ2 KCNQ1 SCN5A
9 long qt syndrome 5 30.9 KCNH2 KCNJ2 KCNQ1 SCN5A
10 long qt syndrome 2 30.9 KCNH2 KCNJ2 KCNQ1 SCN5A
11 brugada syndrome 30.7 CAV3 KCNH2 KCNQ1 SCN5A
12 pure autonomic failure 30.7 GNB3 NPPA
13 long qt syndrome 9 30.7 CAV3 KCNJ2 SCN5A
14 familial atrial fibrillation 30.1 KCNH2 KCNJ2 KCNQ1 NPPA SCN5A
15 ventricular fibrillation, paroxysmal familial, 1 30.0 KCNH2 KCNQ1 SCN5A
16 cardiac conduction defect 29.9 KCNH2 SCN5A
17 cardiac arrhythmia 29.8 KCNH2 KCNQ1 SCN5A
18 cardiac arrest 29.7 CALM1 KCNQ1 SCN5A
19 atrioventricular block 29.7 KCNH2 KCNQ1 NPPB SCN5A
20 third-degree atrioventricular block 29.6 NPPB SCN5A
21 long qt syndrome 1 29.4 CALM1 CAV3 KCNH2 KCNJ2 KCNQ1 SCN5A
22 peripartum cardiomyopathy 29.4 GNB3 SCN5A
23 short qt syndrome 29.0 KCNH2 KCNJ2 KCNQ1 SCN5A
24 heart disease 28.3 KCNH2 KCNJ2 KCNQ1 NPPA NPPB SCN5A
25 long qt syndrome 28.3 CALM1 CAV3 KCNH2 KCNJ2 KCNQ1 SCN5A
26 atrial fibrillation 28.1 KCNH2 KCNJ2 KCNQ1 NPPA NPPB SCN5A
27 syncope, familial vasovagal 12.3
28 ventricular extrasystoles with syncopal episodes - perodactyly - robin sequence 12.1
29 ventricular extrasystoles with syncope, perodactyly, and robin sequence 11.9
30 fainting 11.5
31 ventricular tachycardia, catecholaminergic polymorphic, 2 11.5
32 ventricular tachycardia, catecholaminergic polymorphic, 4 11.5
33 progressive familial heart block, type ia 11.1
34 orthostatic intolerance 11.1
35 atrial standstill 1 11.0
36 wolff-parkinson-white syndrome 11.0
37 postural hypotension 11.0
38 progressive familial heart block, type ib 11.0
39 cardiac arrhythmia, ankyrin-b-related 10.8
40 long qt syndrome 10 10.8
41 muscular dystrophy, limb-girdle, type 2x 10.8
42 long qt syndrome 11 10.8
43 sick sinus syndrome 3 10.8
44 sick sinus syndrome 1 10.8
45 sinoatrial node dysfunction and deafness 10.8
46 dementia, lewy body 10.8
47 progressive familial heart block, type ii 10.8
48 cardiomyopathy, familial hypertrophic, 6 10.6
49 cardiomyopathy, familial hypertrophic, 25 10.6
50 atrial fibrillation, familial, 4 10.6

Graphical network of the top 20 diseases related to Syncope:



Diseases related to Syncope

Symptoms & Phenotypes for Syncope

MGI Mouse Phenotypes related to Syncope:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.5 CAV3 KCNH2 KCNJ2 KCNQ1 NPPA SCN5A
2 muscle MP:0005369 9.1 CAV3 KCNH2 KCNJ2 KCNQ1 NPPA SCN5A

Drugs & Therapeutics for Syncope

Drugs for Syncope (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 240)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amiodarone Approved, Investigational Phase 4,Phase 3 1951-25-3 2157
2
Ranolazine Approved, Investigational Phase 4,Phase 2 95635-55-5, 142387-99-3 56959
3
Testosterone Approved, Investigational Phase 4 58-22-0 6013
4
Losartan Approved Phase 4 114798-26-4 3961
5
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
6
Amlodipine Approved Phase 4 88150-42-9 2162
7
Bisoprolol Approved Phase 4,Phase 3 66722-44-9 2405
8
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
9
Propranolol Approved, Investigational Phase 4,Phase 2 525-66-6 4946
10
Angiotensin II Approved, Investigational Phase 4,Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
11
Midodrine Approved Phase 4 42794-76-3, 133163-28-7 4195
12
Fludrocortisone Approved, Investigational Phase 4 127-31-1 31378
13
Treprostinil Approved, Investigational Phase 4 81846-19-7 6918140 54786
14
Epoprostenol Approved Phase 4 61849-14-7, 35121-78-9 5282411 5280427
15
Methyltestosterone Approved Phase 4 58-18-4 6010
16
Atenolol Approved Phase 4 29122-68-7 2249
17
Donepezil Approved Phase 4 120014-06-4 3152
18 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Adrenergic Agonists Phase 4,Phase 1,Phase 2,Early Phase 1
20 Adrenergic alpha-Agonists Phase 4,Phase 1,Phase 2,Early Phase 1
21 Sodium Channel Blockers Phase 4,Phase 3,Phase 2
22 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3
24 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3
25 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3
26 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3
27 Vasoconstrictor Agents Phase 4,Phase 1,Phase 2,Early Phase 1
28 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3
29 Vasodilator Agents Phase 4,Phase 3,Phase 2
30 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
32 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
33 Potassium Channel Blockers Phase 4,Phase 3
34 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
35 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
36 Tezosentan Phase 4
37 Testosterone undecanoate Phase 4
38
Testosterone enanthate Phase 4 315-37-7 9416
39 calcium channel blockers Phase 4
40 diuretics Phase 4,Phase 3,Phase 1,Phase 2
41 Adrenergic Antagonists Phase 4,Phase 3,Phase 2
42 Adrenergic beta-1 Receptor Antagonists Phase 4,Phase 3
43 Sodium Chloride Symporter Inhibitors Phase 4,Phase 3
44 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 2,Phase 1
45 Sympatholytics Phase 4,Phase 3
46 Natriuretic Agents Phase 4,Phase 3,Phase 1,Phase 2
47 Testosterone 17 beta-cypionate Phase 4
48 Anabolic Agents Phase 4
49 Androgens Phase 4
50 Hormone Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 298)

# Name Status NCT ID Phase Drugs
1 Closed Loop Stimulation for Neuromediated Syncope (SPAIN Study) Unknown status NCT01621464 Phase 4
2 Safety of Amiodarone and Ranolazine Together in Patients With Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo
3 ISSUE3: International Study on Syncope of Uncertain Etiology 3 Completed NCT00359203 Phase 4
4 Clinical Trial for the Prevention of Vasovagal Syncope Completed NCT00118482 Phase 4 fludrocortisone acetate
5 ELIAS: Early Loop-Recorder in Suspected Arrhythmogenic Syncope Completed NCT00170261 Phase 4
6 Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance Completed NCT00060866 Phase 4 Propranolol
7 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01518946 Phase 4 Midodrine HCl;Placebo
8 Comparision of Blood Pressure Variability Between Amlodipine and Losartan Completed NCT01964079 Phase 4 Amlodipine;Losartan
9 Multicenter Automatic Defibrillator Implantation Trial - Reduce Inappropriate Therapy Completed NCT00947310 Phase 4
10 Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis Completed NCT01133054 Phase 4
11 Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication Completed NCT00743522 Phase 4
12 Effects of Testosterone on Myocardial Repolarization Completed NCT03126656 Phase 4 Testosterone Undecanoate
13 A Comparison of Polyglactin 910 and Chromic Gut Suture in the Closure of Punch Biopsy Sites Completed NCT01722994 Phase 4
14 Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin Completed NCT00373360 Phase 4 treprostinil sodium
15 Evaluation of PCLs Using Three EUS-FNA Needles Completed NCT01711294 Phase 4
16 Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Recruiting NCT02123056 Phase 4 Metoprolol;Matching Placebo
17 Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV Recruiting NCT01456481 Phase 4 midodrine hydrochloride;matching placebo
18 Combining Donepezil With Perceptual Learning in Normal and Amblyopic Human The Effect of Donepezil on Perceptual Learning in Adult Amblyopia Recruiting NCT03109314 Phase 4 Donepezil
19 Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART) Recruiting NCT03278509 Phase 4 Metoprolol Succinate;Bisoprolol
20 Syncope: Pacing or Recording in the Later Years Active, not recruiting NCT01423994 Phase 4
21 International Study on Syncope of Uncertain Etiology Terminated NCT00120094 Phase 4
22 A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension Terminated NCT00046163 Phase 4 midodrine hydrochloride (ProAmatine®)
23 Rapid Switch From Flolan to Remodulin in the Outpatient Clinic Terminated NCT00643604 Phase 4 treprostinil sodium
24 Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH Terminated NCT00439946 Phase 4 treprostinil
25 Lactobacillus Reuteri in Treatment of Functional Abdominal Pain and Chronic Constipation in Children Unknown status NCT01587846 Phase 3
26 Stop Vasodepressor Drugs in Reflex Syncope Completed NCT02137278 Phase 3 Vasoactive drug therapies
27 A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease Completed NCT01176240 Phase 3 Droxidopa
28 Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension Completed NCT00095550 Phase 3 Irbesartan/HCTZ;Irbesartan monotherapy;HCTZ monotherapy
29 Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension Completed NCT00095394 Phase 3 Irbesartan/HCTZ;Irbesartan monotherapy
30 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00633880 Phase 3 Placebo;Droxidopa
31 Ablation of Clinical Ventricular Tachycardia Versus Addition of Substrate Ablation on the Long Term Success Rate of VT Ablation Completed NCT01045668 Phase 3
32 Effects of PTH Replacement on Bone in Hypoparathyroidism Completed NCT00395538 Phase 3 PTH 1-34
33 Induction With Foley OR Misoprostol (INFORM) Study Completed NCT01801410 Phase 3 Misoprostol
34 Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD Completed NCT00532493 Phase 3 prazosin
35 Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity Completed NCT00323973 Phase 3 Bisoprolol
36 Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor Completed NCT00308711 Phase 3 Misoprostol vaginal insert 100 mcg;Misoprostol vaginal insert 50 mcg;Dinoprostone vaginal insert (Cervidil)
37 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Completed NCT00782340 Phase 3 Placebo;Droxidopa
38 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00738062 Phase 3 Droxidopa;Placebo
39 Efficacy of Transcatheter Ablation Using Anatomic Approach of Ganglionated Plexi Located in the Right Atrium to Prevent Neuromediated Cardioinhibitory Syncope Recruiting NCT01814228 Phase 3
40 Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections. Recruiting NCT02809131 Phase 3 polymixin/bacitracin;cephalexin, or levofloxacin, or clindamycin;Saline
41 Traumatic Optic Neuropathy Treatment Trial 2 Recruiting NCT03308448 Phase 3 Recombinant human erythropoietin
42 Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction Recruiting NCT00673842 Phase 3
43 A Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe POTS Not yet recruiting NCT03365414 Phase 3 Normal Saline 0.9% Infusion Solution Bag
44 Ballooned Intercostal Drain Trial Not yet recruiting NCT03000504 Phase 3
45 Effect of Chronic Oral Hydration in Patients With Recurrent Unexplained Syncope Terminated NCT00143754 Phase 3
46 A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy Terminated NCT01927055 Phase 3 Droxidopa;Placebo
47 Hydroquinidine Versus Placebo in Patients With Brugada Syndrome Terminated NCT00927732 Phase 3 hydroquinidine;placebo (sugar)
48 Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy Withdrawn NCT01560091 Phase 3 silodosin;Tamsulosin
49 Evaluate the Noninferiority of Medicines Treating Uninfected Pressure Ulcers. Withdrawn NCT02004626 Phase 3 Collagenase;Kollagenase
50 Trial Comparing Ablation With Medical Therapy in Patients With Ventricular Tachycardia Withdrawn NCT01798277 Phase 3 Medical therapy (sotalol or amiodarone)

Search NIH Clinical Center for Syncope

Genetic Tests for Syncope

Genetic tests related to Syncope:

# Genetic test Affiliating Genes
1 Syncope 28

Anatomical Context for Syncope

MalaCards organs/tissues related to Syncope:

38
Heart, Testes, Brain, Thyroid, Skin, Liver, Bone

Publications for Syncope

Articles related to Syncope:

(show top 50) (show all 936)
# Title Authors Year
1
Sympathetic mechanisms in an animal model of vasovagal syncope. ( 29368225 )
2018
2
A single-center randomized controlled trial observing the safety and efficacy of modified step-up graded Valsalva manoeuver in patients with vasovagal syncope. ( 29381726 )
2018
3
Severe deep venous thromboembolism presenting with syncope associated with airplane travel: Case report and public health quandary. ( 29429796 )
2018
4
TUBB3 E410K syndrome with osteoporosis and cough syncope in a patient previously diagnosed with atypical Moebius syndrome. ( 29289389 )
2018
5
A case report of clonidine induced syncope: a review of central actions of an old cardiovascular drug. ( 29433586 )
2018
6
Diagnostic accuracy of ICD-9 code 780.2 for the identification of patients with syncope in the emergency department. ( 29435866 )
2018
7
Prevalence of Pulmonary Embolism in Patients With Syncope. ( 29379959 )
2018
8
Canine case of swallowing syncope that improved after pacemaker implantation. ( 29398674 )
2018
9
Outcomes in syncope research: a systematic review and critical appraisal. ( 29349639 )
2018
10
Selection of the Best of 2017 on the Usefulness of Cardiac Stimulation in the Treatment of Vasovagal Syncope. ( 29422268 )
2018
11
A Population-Based Study of Syncope in the Young. ( 29407009 )
2018
12
AmbulatoryA diagnostic ECG monitoring for syncope and collapse: An assessment of clinical practice in the United States. ( 29314105 )
2018
13
Implantable loop recorders in patients with unexplained syncope:Clinical predictors of pacemaker implantation. ( 29399750 )
2018
14
Orthostatic blood pressure recovery patterns in suspected syncope in the emergency department. ( 29367218 )
2018
15
Tilt testing and what you should know about it - Experience with 835 consecutive patients with syncope of unknown origin. ( 29429639 )
2018
16
Differential diagnosis of unexplained falls in dementia: Results of "Syncope & Dementia" registry. ( 29398249 )
2018
17
Experience of a rapid access falls and syncope service at a teaching hospital in Kuala Lumpur. ( 28889130 )
2017
18
Role of emergency department observation units in the management of patients with unexplained syncope: a critical review and meta-analysis. ( 29306267 )
2017
19
Monitoring of cerebral oximetry during head-up tilt test in adults with history of syncope and orthostatic intolerance. ( 29036615 )
2017
20
Discriminatory Value of Orthostatic Vital Signs in the Emergency Department Evaluation of Syncope. ( 28844271 )
2017
21
Bradycardia, Syncope, and Left Ventricular Noncompaction Cardiomyopathy. ( 28645472 )
2017
22
Prevalence of pulmonary embolism in patients presenting to the emergency department with syncope. ( 28811209 )
2017
23
Syncope and orthostatic hypotension: early markers of cardiac disease in the general population. ( 28814494 )
2017
24
Effect of Citalopram for the Treatment of Neurocardiogenic Syncope. ( 28816725 )
2017
25
Use of Biotronik closed loop pacemaker to treat recurrent syncope in pediatric patient with dysautonomia. ( 28491761 )
2017
26
Giant Left Atrial Myxoma Masquerading as Cough-Syncope Syndrome. ( 28815190 )
2017
27
Masquerading bundle branch block as a presenting manifestation of complete atrioventricular block that caused syncope. ( 28627977 )
2017
28
The Use of Echocardiography for Pediatric Patients Presenting with Syncope. ( 28888565 )
2017
29
Impact of pharmacological spasm provocation test in patients with a history of syncope. ( 28905210 )
2017
30
Cor triatriatum sinistrum: presentation of syncope and atrial tachycardia. ( 28196823 )
2017
31
Dose-Response Relationship between the Risk of Vasovagal Syncope and Body Mass Index or Systolic Blood Pressure in Young Adults Undergoing Blood Tests. ( 28810256 )
2017
32
Syncope Due to a Free-floating Left Atrial Thrombus. ( 28943579 )
2017
33
Role of syncope in predicting adverse outcomes in patients with suspected Brugada syndrome undergoing standardized flecainide testing. ( 29309564 )
2017
34
Stressful medical explanation may cause syncope in patients with emotion-triggered neurocardiogenic syncope. ( 28925543 )
2017
35
Comparison of Specific Fainting Characteristics Between Youth With Tilt-Induced Psychogenic Nonsyncopal Collapse Versus Reflex Syncope. ( 28236458 )
2017
36
Syncope and paroxysmal atrioventricular block. ( 29255501 )
2017
37
Prevalence of pulmonary embolism in patients presenting with syncope. A systematic review and meta-analysis. ( 28947223 )
2017
38
Syncope, Junctional Premature Complexes, and Pseudo-Type II Atrioventricular Block. ( 29395000 )
2017
39
Recurrent syncope due to glossopharyngeal neuralgia. ( 28491772 )
2017
40
Prohormones in the Early Diagnosis of Cardiac Syncope. ( 29426039 )
2017
41
Late-onset Pompe disease in a 54 year-old sportsman with an episode of syncope: a case report. ( 28925476 )
2017
42
Syndromes of orthostatic intolerance and syncope in young adults. ( 28674628 )
2017
43
Acute onset autonomic dysfunction and orthostatic syncope as an early manifestation of HIV infection. ( 28856462 )
2017
44
Prevalence of Pulmonary Embolism in Patients Presenting to the Emergency Department for Syncope. ( 28759507 )
2017
45
Sniffing and gasping to prevent syncope? ( 28863464 )
2017
46
Definitive Pacing Therapy in Patients With Neuromediated Syncope. Lessons From the SPAIN Study. ( 29295807 )
2017
47
Syncope During Competitive Events: Interrogating Heart Rate Monitor Watches May Be Useful! ( 28807079 )
2017
48
The effects of body weight status on orthostatic intolerance and predisposition to noncardiac syncope. ( 28112481 )
2017
49
Perservative paroxysmal atrioventricular block : Cardiac syncope misdiagnosed as anxiety for more than 20A years. ( 28840364 )
2017
50
Role of closed loop stimulation pacing (CLS) in vasovagal syncope. ( 28895151 )
2017

Variations for Syncope

Expression for Syncope

Search GEO for disease gene expression data for Syncope.

Pathways for Syncope

Pathways related to Syncope according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.66 CALM1 GNB3 KCNH2 KCNJ2 KCNQ1
2
Show member pathways
12.4 CALM1 GNB3 KCNJ2 KCNQ1
3
Show member pathways
12.16 GNB3 NPPA NPPB
4 12.01 CALM1 GNB3 KCNH2 KCNJ2 KCNQ1
5
Show member pathways
11.9 CALM1 KCNJ2 KCNQ1
6
Show member pathways
11.89 CALM1 CAV3 KCNH2 KCNJ2 KCNQ1 NPPA
7
Show member pathways
11.85 CALM1 NPPA NPPB
8
Show member pathways
11.79 GNB3 KCNH2 KCNJ2 KCNQ1
9 11.57 CAV3 GNB3 KCNH2 KCNQ1 SCN5A
10
Show member pathways
11.42 CALM1 KCNQ1 SCN5A
11 11.2 KCNH2 KCNJ2 KCNQ1 SCN5A
12 11.08 CALM1 CAV3
13 10.84 NPPA NPPB
14 10.74 KCNJ2 KCNQ1

GO Terms for Syncope

Cellular components related to Syncope according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.92 CALM1 CAV3 GNB3 KCNH2 KCNJ2 KCNQ1
2 protein complex GO:0043234 9.67 CALM1 CAV3 NPPA NPPB
3 membrane raft GO:0045121 9.58 CAV3 KCNQ1 SLC6A2
4 cell surface GO:0009986 9.56 CAV3 KCNH2 SCN5A SLC6A2
5 voltage-gated potassium channel complex GO:0008076 9.33 KCNH2 KCNJ2 KCNQ1
6 intercalated disc GO:0014704 9.13 CAV3 KCNJ2 SCN5A
7 T-tubule GO:0030315 8.8 CAV3 KCNJ2 SCN5A

Biological processes related to Syncope according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.97 KCNH2 KCNJ2 KCNQ1 SCN5A
2 transmembrane transport GO:0055085 9.95 CALM1 KCNH2 KCNQ1 SCN5A SLC6A2
3 ion transmembrane transport GO:0034220 9.85 CALM1 KCNQ1 SCN5A
4 protein folding GO:0006457 9.83 GNB3 NPPA NPPB
5 potassium ion transport GO:0006813 9.82 KCNH2 KCNJ2 KCNQ1
6 potassium ion transmembrane transport GO:0071805 9.81 KCNH2 KCNJ2 KCNQ1
7 regulation of ion transmembrane transport GO:0034765 9.8 KCNH2 KCNJ2 KCNQ1 SCN5A
8 regulation of blood pressure GO:0008217 9.71 GNB3 NPPA NPPB
9 cardiac muscle contraction GO:0060048 9.69 KCNH2 KCNQ1 SCN5A
10 regulation of heart contraction GO:0008016 9.67 CAV3 KCNQ1
11 cardiac conduction GO:0061337 9.67 KCNH2 KCNJ2 KCNQ1 SCN5A
12 membrane depolarization during action potential GO:0086010 9.66 KCNH2 SCN5A
13 cGMP biosynthetic process GO:0006182 9.65 NPPA NPPB
14 regulation of cardiac muscle contraction GO:0055117 9.65 CALM1 CAV3
15 positive regulation of heart rate GO:0010460 9.65 KCNQ1 NPPA
16 regulation of heart rate GO:0002027 9.65 CALM1 CAV3 SCN5A
17 regulation of blood vessel size GO:0050880 9.64 NPPA NPPB
18 cardiac muscle cell action potential involved in contraction GO:0086002 9.63 KCNJ2 SCN5A
19 positive regulation of potassium ion transmembrane transport GO:1901381 9.63 KCNH2 KCNJ2 KCNQ1
20 regulation of cardiac muscle cell contraction GO:0086004 9.62 KCNJ2 SCN5A
21 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.62 KCNJ2 SCN5A
22 positive regulation of cardiac muscle contraction GO:0060452 9.61 KCNQ1 NPPA
23 membrane repolarization GO:0086009 9.61 KCNH2 KCNQ1
24 regulation of membrane repolarization GO:0060306 9.61 KCNH2 KCNJ2 KCNQ1
25 receptor guanylyl cyclase signaling pathway GO:0007168 9.6 NPPA NPPB
26 regulation of ventricular cardiac muscle cell membrane depolarization GO:0060373 9.59 CAV3 SCN5A
27 atrial cardiac muscle cell action potential GO:0086014 9.58 KCNQ1 SCN5A
28 negative regulation of potassium ion transmembrane transport GO:1901380 9.58 CAV3 KCNH2
29 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.58 KCNH2 KCNJ2 KCNQ1
30 potassium ion export GO:0071435 9.57 KCNH2 KCNQ1
31 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.56 KCNH2 KCNQ1
32 potassium ion export across plasma membrane GO:0097623 9.52 KCNH2 KCNQ1
33 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.5 KCNQ1 NPPA SCN5A
34 regulation of heart rate by cardiac conduction GO:0086091 9.46 KCNH2 KCNJ2 KCNQ1 SCN5A
35 membrane repolarization during action potential GO:0086011 9.43 KCNH2 KCNJ2 KCNQ1
36 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.26 CAV3 KCNH2 KCNQ1 SCN5A
37 ventricular cardiac muscle cell action potential GO:0086005 8.92 CAV3 KCNH2 KCNQ1 SCN5A

Molecular functions related to Syncope according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 scaffold protein binding GO:0097110 9.5 KCNH2 KCNQ1 SCN5A
2 alpha-tubulin binding GO:0043014 9.48 CAV3 SLC6A2
3 delayed rectifier potassium channel activity GO:0005251 9.46 KCNH2 KCNQ1
4 voltage-gated ion channel activity GO:0005244 9.46 KCNH2 KCNJ2 KCNQ1 SCN5A
5 inward rectifier potassium channel activity GO:0005242 9.43 KCNH2 KCNJ2
6 nitric-oxide synthase binding GO:0050998 9.4 CAV3 SCN5A
7 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.37 KCNH2 KCNQ1
8 hormone receptor binding GO:0051427 9.26 NPPA NPPB
9 ion channel binding GO:0044325 9.26 CALM1 CAV3 KCNQ1 SCN5A
10 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 8.8 KCNH2 KCNJ2 KCNQ1

Sources for Syncope

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....